Abstract: The present invention relates to 5-(alkylidene-cycloalkyl)-pyrazoles and 5-(alkylidene-heterocyclyl)-pyrazoles of the formula I: wherein the ring of the formula (R5)-A-(SOmR4), m, B, ring G, R1 through R7 are as defined in the specification, to pharmaceutical compositions containing them and to their medicinal use. The compounds of the invention are useful in the treatment or alleviation of inflammation and other inflammation associated disorders, such as arthritis, colon cancer, and Alzheimer's disease in mammals, preferably humans, dogs, cats and livestock animals.
Abstract: The present invention provides a device, preferably a collar or ear tag, capable of the controlled, sustained release of an effective amount of an active ingredient that can protect an animal against arthropod pests, comprising a reservoir containing a novel gel formulation comprising a fatty acid, an organic solvent which is a linear aliphatic ester, a silicone-based fluid, or a combination thereof, and an active ingredient that can protect the animal against one or more arthropod pests.
Abstract: This invention relates to compounds of the formula
wherein a, R1, R2, R3, R4, R5, R6 and X are each as defined above, and to pharmaceutically acceptable salts thereof, useful as potent antibacterial and antiprotozoal agents that may be used to treat various bacterial and protozoal infections and disorders related to such infections. The invention also relates to pharmaceutical compositions containing the compounds of formula I and to methods of treating bacterial and protozoal infections by administering the compounds of formula I.
Abstract: This invention provides submicron oil-in-water emulsions useful as a vaccine adjuvant for enhancing the immunogenicity of antigens. The present invention also provides vaccine compositions containing an antigen combined with such emulsions intrinsically or extrinsically. Methods of preparing the emulsions and vaccines are also provided by the present invention.
Type:
Application
Filed:
April 5, 2004
Publication date:
December 23, 2004
Applicants:
PFIZER INC., PFIZER PRODUCTS INC.
Inventors:
Paul J. Dominowski, Pamela Klose, Richard L. Krebs, Ramasamy Mannan
Abstract: The subject invention relates to 3-azabicyclo[3.2.1]octane derivatives, pharmaceutical compositions comprising such derivatives and methods of using such derivatives to treat disease states, disorders and conditions mediated by opioid receptors. The subject invention also particularly relates to using such derivatives to treat certain disorders and conditions, for example irritable bowel syndrome, drug addiction, depression, anxiety, schizophrenia and eating disorders, among others.
Type:
Application
Filed:
April 14, 2004
Publication date:
December 23, 2004
Applicant:
Pfizer Inc
Inventors:
Jotham W. Coe, Stanton McHardy, Crystal G. Bashore
Abstract: This invention relates to methods, pharmaceutical compositions and kits useful in promoting bone formation and/or preventing bone loss and lowering blood cholesterol. The compositions are comprised of an estrogen agonist/antagonist as a first active component and a statin as a second active component and a pharmaceutically acceptable vehicle, carrier or diluent. The compositions and methods of treatment are effective while substantially reducing the concomitant liability of adverse effects associated with estrogen administration.
Type:
Application
Filed:
May 6, 2004
Publication date:
December 23, 2004
Applicant:
Pfizer Inc
Inventors:
Wesley W. Day, Andrew G. Lee, David D. Thompson
Abstract: Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein.
Abstract: This invention relates to compounds of the formula 1:
and to pharmaceutically acceptable salts and solvates thereof wherein X1, X2, R2, R8, R9, R10 and R11 are as defined herein. The compounds of formula 1 are antibacterial and antiprotozoal agents that may be used to treat various bacterial and protozoal infections and disorders related to such infections. The invention also relates to pharmaceutical compositions containing the compounds of formula 1 and to methods of treating bacterial and protozoal infections by administering the compounds of formula 1.
Abstract: The present invention relates to polynucleotide molecules comprising sequences encoding avec gene products, which polynucleotide molecules can be used to alter the ratio or amount of class 2:1 avermectins produced in fermentation cultures of Streptomyces avermitilis. AveC genes, homologs and partial homologs thereof are described for S. avermitilis , S. hygroscopicus, and S. griseochromogenes, respectively. The present invention further relates to vectors, host cells, and mutant strains of Streptomyces avermitilis in which the avec gene has been inactivated, or mutated so as to change the ratio or amount of class 2:1 avermectins produced.
Type:
Grant
Filed:
November 27, 2002
Date of Patent:
December 21, 2004
Assignee:
Pfizer Inc.
Inventors:
Kim J. Stutzman-Engwall, Hamish McArthur, Yoshihiro Katoh
Abstract: Corticotropin-releasing factor (CRF) antagonists having the formulae
wherein the dashed lines, A, B, Y, Z, G, R3, R4, R5, R6, R16 and R17 are as defined in the application, and processes for preparing them. These compounds and their pharmaceutically acceptable salts are useful in the treatment disorders including CNS and stress-related disorders.
Abstract: Non-peptide GnRH agents that inhibit the effect of gonadotropin-releasing hormone are described. Such agents are useful for treating mammalian reproductive disorders and steroid hormone-dependent tumors as well as for regulating fertility, where suppression of gonadotropin release is indicated.
Type:
Grant
Filed:
February 11, 2003
Date of Patent:
December 21, 2004
Assignee:
Pfizer, Inc.
Inventors:
Lance C. Christie, Mark B. Anderson, Jun Feng, Yufeng Hong, Ved P. Pathak, Ranjan J. Rajapakse, Eileen V. Tompkins, Haresh Vazir, Haitao Li
Abstract: A method of treating a female suffering from FSD, in particular FSAD, is described. The method comprises delivering to the female an agent that is capable of potentiating cAMP in the sexual genitalia; wherein the agent is in an amount to cause potentiation of cAMP in the sexual genitalia of the female. The agent may be admixed with a pharmaceutically acceptable carrier, diluent or excipient.
Type:
Application
Filed:
October 15, 2003
Publication date:
December 16, 2004
Applicant:
Pfizer Inc
Inventors:
Graham Nigel Maw, Christopher Peter Wayman
Abstract: A medication organizer system includes an arrangement of day of the week containers with each container divided into separate time of the day compartments. Each time of the day compartment has pictorial indicia which readily signifies a specific respective time of the day. A medication dosage instruction sheet is provided with medication/pill identifying pictorial indicia and an imprinted grid which tracts the container and compartment arrangement; the grid having juxtaposed imprinted pictorial indicia corresponding to the compartment pictorial indicia. A sheet of adhesive backed peel-off numerals is provided, whereby a peeled-off numeral corresponding to correct number of prescribed pills is adhesively inserted onto the medication dosage instruction sheet juxtaposed to the grid. The peeled-off numeral signifies the prescribed number of pills are to be taken.